Replies to post #24312 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 2Q21 Results by Business Segment

 
                  %Corp      YoY Growth  
 Segment          Sales   (const currency) 
 Medical devices*  36%       +45%   
 Diagnostics       32%       +57%   
 Nutrition         21%       +10%   
 Drugs†            12%       +15%

2Q21 COVID-19 diagnostics sales were $1.5B, 46% of total 2Q21 diagnostics sales.

65% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.

[DewDiligence]

ABT 3Q21 results—2021_non-GAAP_EPS_guidance—>$5.00-5.10 (from $4.30-4.50):

https://abbott.mediaroom.com/2021-10-20-Abbott-Reports-Third-Quarter-2021-Results-Achieves-Strong-Double-Digit-Earnings-Growth-and-Raises-Guidance

3Q21 COVID-diagnostics sales were $1.9B.